Abstract
Aripiprazole, a dopamine stabilizing atypical antipsychotic is used in treatment of tardive dyskinesia caused by other neuroleptics. Tardive dyskinesia is rarely caused by Aripiprazole and has only been documented in high risk patients i.e., female gender, advanced age, affective illness, coexisting neurological disorders. Here the author describes two atypical cases of tardive dyskinesia associated with Aripiprazole. First case of tardive dyskinesia was observed in a neuroleptic naïve young adult male with paranoid illness after six months of treatment with Aripiprazole upon addition of Fluoxetine and the second case was a middle aged female with affective illness where dyskinetic movements appeared after stopping Aripiprazole. The role of Fluoxetine in causing tardive dyskinesia with Aripiprazole and covert dyskinesia due to Aripiprazole with appropriate management is discussed.
Keywords: Aripiprazole, covert dyskinesia, tardive dyskinesia.
Current Drug Safety
Title:Tardive Dyskinesia and Covert Dyskinesia with Aripiprazole: A Case Series
Volume: 11 Issue: 1
Author(s): Suravi Patra
Affiliation:
Keywords: Aripiprazole, covert dyskinesia, tardive dyskinesia.
Abstract: Aripiprazole, a dopamine stabilizing atypical antipsychotic is used in treatment of tardive dyskinesia caused by other neuroleptics. Tardive dyskinesia is rarely caused by Aripiprazole and has only been documented in high risk patients i.e., female gender, advanced age, affective illness, coexisting neurological disorders. Here the author describes two atypical cases of tardive dyskinesia associated with Aripiprazole. First case of tardive dyskinesia was observed in a neuroleptic naïve young adult male with paranoid illness after six months of treatment with Aripiprazole upon addition of Fluoxetine and the second case was a middle aged female with affective illness where dyskinetic movements appeared after stopping Aripiprazole. The role of Fluoxetine in causing tardive dyskinesia with Aripiprazole and covert dyskinesia due to Aripiprazole with appropriate management is discussed.
Export Options
About this article
Cite this article as:
Patra Suravi, Tardive Dyskinesia and Covert Dyskinesia with Aripiprazole: A Case Series, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666150921104343
DOI https://dx.doi.org/10.2174/1574886310666150921104343 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs
Current Topics in Medicinal Chemistry Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases
Current Pharmaceutical Design Polypharmacy- Purpose, Benefits and Limitations
Current Medicinal Chemistry New Insights into the Surgical Management of Tetralogy of Fallot: Physiological Fundamentals and Clinical Relevance
Current Pediatric Reviews α7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson’s Disease
Current Drug Targets Innovations to Control the Environment for Persons with Movement Disorders: Support in Home Care
Recent Patents on Biomedical Engineering (Discontinued) Neuroleptics and Migraine
Central Nervous System Agents in Medicinal Chemistry Current Status of Tyrosine Hydroxylase in Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Substance Abuse and Movement Disorders
Current Drug Abuse Reviews Mitochondrial-Associated Metabolic Changes and Neurodegeneration in Huntingtons Disease - from Clinical Features to the Bench
Current Drug Targets Editorial (Thematic Issue: Recent Progress in Drug Discovery for Parkinson's Disease)
Current Topics in Medicinal Chemistry Serotonin Reuptake Inhibitors: The Corner Stone in Treatment of Depression for Half a Century – A Medicinal Chemistry Survey
Current Topics in Medicinal Chemistry Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets Mathematical Models of Behavior of Individual Animals
Current Pharmaceutical Design Antidepressant Related Movement Disorders in the Elderly
Current Psychiatry Reviews Kynurenines in the Central Nervous System: Recent Developments
Central Nervous System Agents in Medicinal Chemistry Pharmacotherapy of Schizophrenia: The Past, Present and Future
Current Drug Therapy Chromosomal Micro-aberration in a Saudi Family with Juvenile Myoclonic Epilepsy
CNS & Neurological Disorders - Drug Targets Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Differences in Medication Adherence, Satisfaction and Clinical Symptoms in Schizophrenic outpatients Taking Different Antipsychotic Regimens
Current Drug Safety